Hematologic MalignancyNCT05417971
Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation
An observational study of Hematologic Malignancy, run by Northside Hospital, Inc. at 1 site in United States.
Trial summary
This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hematologic Malignancy
- What is being tested?
- Fludarabine
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- 29 Aug 2022to 31 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Male or female patients with any hematologic malignancy that requires an allogeneic transplant from a halpo-identical matched related donor
Who may be able to join
- Availability of 3/6 - 5/6 matched related donor with a negative HLA-cross match in the host vs. graft direction willing to donate peripheral blood stem cells
- KPS >/= 70%
- Hematologic malignancy requiring allogeneic transplantation, with a predicted high risk of relapse following non-myeloablative, low intensity conditioning.
Who cannot join
- Poor cardiac function (LVEF <45%)
- Poor pulmonary function (FEV, FVC, DLCO <60%)
- Poor liver function (bilirubin >/= 2.5mg/dL; AST or ALT >3xULN)
- Poor renal function (creatinine clearance <40mL/min)
- HIV-positive; active HepB or HepC
- Uncontrolled infection
- Pregnant female or not able to practice adequate contraception
- Debilitating medical or psychiatric illness which would preclude their giving informed consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Caitlin Guzowski
Atlanta, Georgia, 30342
Caitlin Guzowski, MBA, MHA, 404-851-8523, caitlin.guzowski@northside.com
H. Kent Holland, MD
About this study
Official title: A Phase II Trial of Reduced Intensity Fludarabine and Total Body Irradiation-Based Conditioning Prior to Haplo-Identical Transplantation for Patients With Hematologic Malignancies
This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source.
- Conditions
- Hematologic Malignancy
- Being tested
- Fludarabine
- Medical subject headings
- Hematologic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FludarabineOther
Also called Total Body Irradiation
Reduced-intensity fludarabine with intermediate-dose TBI
What is being measured
The primary outcome is the main question the study is designed to answer.
Compare the time to recovery of circulating neutrophils and platelets of all patients to determine incidence of graft rejection
Measured: 30 days after transplant
Secondary outcomes (6)
Number of patients who are still alive as assessed by survival status at certain timepoints after transplant
Measured: 36 months after transplant
Number of patients with relapsed disease as assessed by labs, bone marrow biopsies and radiological scans at certain timepoints after transplant
Measured: 36 months after transplant
Number of patients with evidence of graft versus host disease as assessed by weekly progress notes after transplant
Measured: 36 months after transplant
Number of participants who died in the absence of relapse or progression as assessed by survival status at certain timepoints after transplant
Measured: 1 year after transplant
Number of participants with responses to treatment as assessed by labs, bone marrow biopsies and radiological scans at certain timepoints after transplant
Measured: 36 months after transplant
Number of participants with treatment-related adverse events as assessed by CTCAE v.5.0
Measured: 90 days after transplant
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jun 2022
- Study start29 Aug 2022
- Primary completion31 Mar 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hematologic MalignancyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Northside Hospital, Inc.
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Scott Solomon, MD, Principal investigator, BMTGA
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05417971
- Sponsor's protocol ID
- NSH 1347
- Status last verified
- Oct 2026
- First submitted
- 31 May 2022
- Last updated
- 14 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase II Trial of Reduced Intensity Fludarabine and Total Body Irradiation-Based Conditioning Prior to Haplo-Identical Transplantation for Patients With Hematologic Malignancies
- ClinicalTrials.gov ID
- NCT05417971
- Acronym / sponsor ID
- NSH 1347
- Conditions
- Hematologic Malignancy
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Northside Hospital, Inc.University, hospital or other
- Study start
- 29 Aug 2022 (actual)
- Primary completion
- 31 Mar 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 14 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Male or female patients with any hematologic malignancy that requires an allogeneic transplant from a halpo-identical matched related donor
Key inclusion criteria (3 listed)
- Availability of 3/6 - 5/6 matched related donor with a negative HLA-cross match in the host vs. graft direction willing to donate peripheral blood stem cells
- KPS >/= 70%
- Hematologic malignancy requiring allogeneic transplantation, with a predicted high risk of relapse following non-myeloablative, low intensity conditioning.
Key exclusion criteria (8 listed)
- Poor cardiac function (LVEF <45%)
- Poor pulmonary function (FEV, FVC, DLCO <60%)
- Poor liver function (bilirubin >/= 2.5mg/dL; AST or ALT >3xULN)
- Poor renal function (creatinine clearance <40mL/min)
- HIV-positive; active HepB or HepC
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FludarabineAlso: Total Body IrradiationReduced-intensity fludarabine with intermediate-dose TBI | Other | – |
Primary outcome
Compare the time to recovery of circulating neutrophils and platelets of all patients to determine incidence of graft rejection
Time frame: 30 days after transplant
6 secondary outcomes
Number of patients who are still alive as assessed by survival status at certain timepoints after transplant
Time frame: 36 months after transplant
Number of patients with relapsed disease as assessed by labs, bone marrow biopsies and radiological scans at certain timepoints after transplant
Time frame: 36 months after transplant
Number of patients with evidence of graft versus host disease as assessed by weekly progress notes after transplant
Time frame: 36 months after transplant
Number of participants who died in the absence of relapse or progression as assessed by survival status at certain timepoints after transplant
Time frame: 1 year after transplant
Number of participants with responses to treatment as assessed by labs, bone marrow biopsies and radiological scans at certain timepoints after transplant
Time frame: 36 months after transplant
Number of participants with treatment-related adverse events as assessed by CTCAE v.5.0
Time frame: 90 days after transplant
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Hematologic Malignancy
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Active, not recruitingPhase 3
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Multiple Myeloma
Active, not recruitingPhase 1/2
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Multiple Myeloma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Scott Solomon, MD principal investigator
BMTGA
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hematologic Malignancy, run by Northside Hospital, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Stacey Brown (404-480-7965, stacey.brown@northside.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Compare the time to recovery of circulating neutrophils and platelets of all patients to determine incidence of graft rejection (time frame: 30 days after transplant). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Oct 2026.